The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy.

Sequential RT plus anti–PD-L1 extended median survival from 17 days to 23 days versus RT alone, but the survival difference did not reach statistical significance ( Figure 8C ).

also in 111,027 other papers